Dapagliflozin links renal protection in diabetic kidney disease to YAP-driven ferroptosis
SGLT2 inhibitors continue to widen their mechanistic reach beyond glycemic control, and this study places dapagliflozin inside a new cellular circuit in diabetic kidney disease. In human kidney tissue, nuclear accumulation of Yes-associated protein 1, or YAP, rose alongside ferroptosis markers and fell in step with renal function. In the diabetic rat model, the drug reduced renal dysfunction, tubular injury, and fibrosis while also damping YAP activation and ferroptotic injury. The work offers a coherent path from glucose transport blockade to tubular survival, with the proximal tubule emerging as the central battleground.
The signal is not simply metabolic. It points to a programmed form of cell death that depends on iron handling, lipid peroxidation, and mitochondrial damage, all of which can amplify tubular loss in a kidney already stressed by chronic hyperglycemia. By anchoring the findings to a YAP/TEAD4–ACSL4 transcriptional axis, the study gives a molecular explanation for part of the glucose-independent renoprotection that has made this drug class so clinically consequential.
Nuclear YAP accumulation tracked with ferroptosis and worse renal function in human tissue
Kidney samples from people with diabetic kidney disease showed a pattern that fits a direct injury pathway rather than a passive bystander effect. Nuclear YAP accumulation correlated positively with ACSL4 and 4-hydroxynonenal, two markers closely tied to ferroptotic lipid injury, and correlated negatively with renal function. In practical terms, the more YAP translocated to the nucleus, the more the tissue looked like it was being pushed toward iron-dependent membrane damage.
That relationship matters because YAP is not just a structural protein drifting through the cell. Once in the nucleus, it acts as a transcriptional co-activator, turning on genes that can reshape survival, proliferation, and stress responses. Here, the association with ferroptosis markers suggests that YAP is not merely present in the diseased kidney; it is participating in a transcriptional program that makes tubular cells more vulnerable to oxidative collapse.
Dapagliflozin reduced tubular injury, fibrosis, and YAP activation in diabetic rats
In the diabetic rat model, dapagliflozin improved renal dysfunction and reduced tubular injury and fibrosis. The same treatment also lowered YAP activation and suppressed ferroptosis, placing the drug’s renoprotective effect upstream of the cell-death process rather than downstream of it. The result is biologically plausible in the kidney, where chronic hyperglycemia creates a dense mix of oxidative stress, iron dysregulation, and epithelial stress signaling.
One sentence captures the core divergence: renal injury eased when the YAP-ferroptosis axis was quieted.
Fibrosis deserves special attention here. Tubular loss does not remain a localized epithelial problem for long; it feeds interstitial scarring, alters microvascular integrity, and accelerates functional decline. By reducing the tubular ferroptotic burden, dapagliflozin may interrupt the feed-forward cycle that converts metabolic injury into fixed structural damage.
High glucose pushed tubular cells into ferroptosis through YAP and ACSL4
The cell-culture experiments sharpened the mechanism. In high-glucose-treated renal tubular epithelial cells, YAP promoted nuclear translocation, increased ACSL4 and transferrin receptor expression, raised iron accumulation, damaged mitochondria, and drove ferroptotic cell death. Each step fits a recognizable ferroptosis phenotype: more iron entry, more lipid susceptibility, more organelle injury, and less cellular resilience.
Transferrin receptor upregulation is especially important because it suggests increased iron import, which can intensify the substrate available for oxidative injury. ACSL4, in turn, is a well-established ferroptosis determinant because it enriches membranes with polyunsaturated fatty acids that are easy targets for peroxidation. When YAP raises both, the cell becomes chemically primed for the kind of membrane destruction that ferroptosis requires.
YAP knockdown and pharmacologic inhibition both reduced this process, confirming that YAP sits upstream in the injury sequence rather than merely reflecting cellular distress after the fact. The consistency across genetic and pharmacologic interruption strengthens the causal interpretation. It also makes the pathway therapeutically interesting, because a drug that already reaches the kidney appears capable of blunting a transcriptional injury program with no need for a separate ferroptosis-targeting compound.
TEAD4 and the ACSL4 promoter formed the mechanistic bridge
The transcriptional mechanism was traced further downstream to TEAD4. YAP and TEAD4 enhanced ACSL4 promoter activity through a conserved TEAD-binding motif, and dapagliflozin suppressed this effect. This is the kind of mechanistic link that moves a hypothesis from correlation to regulatory architecture: YAP is not only present, but it is binding into a defined transcriptional complex that turns a ferroptosis gene on.
The promoter data matter because they explain how high glucose can translate into a durable cellular phenotype. Once the YAP/TEAD4 complex activates ACSL4, the tubular cell becomes more susceptible to membrane peroxidation even if the original glucose signal fluctuates. That gives the kidney a molecular memory of injury, which is one reason diabetic kidney disease can progress long after glycemic exposure has become more controlled.
What this pathway adds to the renoprotection story
For nephrology, the main contribution is conceptual as much as experimental. The study positions ferroptosis as a biologically important component of diabetic tubular injury and places YAP at the top of that cascade. It also supports a broader view of SGLT2 inhibition as a class effect that extends beyond natriuresis and glucose wasting into epithelial stress biology.
The findings do not replace the clinical evidence base for SGLT2 inhibitors; they deepen the rationale for it. If part of the benefit comes from dampening YAP-dependent ferroptosis, then the kidney-protective effect may be partially explained by preservation of tubular integrity under chronic metabolic strain. That creates a mechanistic bridge between observed clinical benefit and intracellular injury control.
Several questions remain open inside the study design itself. The work is preclinical, built on human tissue correlations, a diabetic rat model, and cell culture experiments, so it cannot define how much of the clinical benefit in patients depends on this pathway. It also does not establish whether the same axis operates uniformly across different stages of diabetic kidney disease or across different SGLT2 inhibitors. Even so, the central finding is sharp: dapagliflozin blunted diabetic kidney injury by suppressing a YAP/TEAD4-ACSL4 program that drives ferroptotic tubular death.